The Role of Prolactin in Postmenopausal Breast Cancer

催乳素在绝经后乳腺癌中的作用

• 批准号: 6948505
• 负责人: FRANCESMARY MODUGNO
• 金额: $ 7.43万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-14 至 2007-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6948505
• 关键词: biomarker; breast neoplasms; cancer prevention; cancer risk; estrogen receptors; female; hormone therapy; human data; meta analysis; neoplasm /cancer epidemiology; postmenopause; progesterone receptors; prolactin; women' s health

DESCRIPTION (provided by applicant): Laboratory data suggests that prolactin (PRL), a hormone that controls breast development and lactation, may also play a role in breast carcinogenesis. Data in humans has been sparse consisting of mainly case-control studies with extremely small sample sizes. Only one large prospective study (the Nurses" Health Study) has examined the question, noting a significant positive association between plasma PRL levels similar in magnitude to that of estrogen and breast cancer. If validated, these findings would suggest additional areas for focused research into the development of chemopreventive agents, similar to the development of SERMS for breast cancer prevention. Thus, a large prospective study is urgently needed. The objective of this application is to prospectively evaluate the extent to which PRL levels are related to breast cancer in postmenopausal women. We will specifically test the following hypothesis: Among postmenopausal women, serum prolactin levels are positively associated with breast cancer risk. We will further evaluate the effects of sex steroid hormones and growth factors levels on the prolactin-breast cancer association. As a secondary aim, we will explore the relationship of prolactin levels to clinical characteristics of breast cancer, including tumor stage, grade and ER/PR status. We will undertake a case-cohort study within the Study of Osteoporotic Fractures (SOF). SOF is a prospective study that collected risk factor data and banked fasting serum on 9704 postmenopausal women in the United States. Since 1986, 481 women were diagnosed with breast cancer after enrollment. We will measure prolactin levels in the prospectively-collected serum of 375 women who developed breast cancer during follow-up and 375 SOF participants who did not develop the disease during follow-up. To assess the relationship between prolactin and breast cancer, we will use Cox regression models controlling for covariates such as age, family history, age at first birth, age at menarche, age at menopause, past use of hormone replacement therapy, parity, ever breast fed, and history of benign breast disease, as well as factors affecting prolactin. A positive finding in our study will support the development of breast cancer chemopreventive agents aimed at the prolactin pathway. Approval for this study has already been obtained from SOF and we can begin the study as soon as funding is obtained.

描述（由申请人提供）： 实验室数据表明，控制乳房发育和泌乳的激素催乳素（PRL）也可能在乳腺癌发生中发挥作用。人类的数据稀疏，主要由样本量极小的病例对照研究组成。只有一项大型前瞻性研究（护士“健康研究）已经检查了这个问题，指出血浆PRL水平与雌激素和乳腺癌相似的大小相似的水平之间存在显着的正相关。如果经过验证，这些发现将暗示将重点研究集中在化学预防剂的发展中，类似于对乳腺癌预防的培训的范围，从而对乳腺癌预防的范围进行了类似的范围。与绝经后妇女的乳腺癌有关。地位。 375个在随访期间没有发展疾病的SOF。针对催乳素途径的癌症化学预防剂已经从SOF获得，我们可以在获得资金后立即开始研究。